MAPK3 and cancer: BVD-523 (ulixertinib), ASN-007 and LY-3214996 are such inhibitors that have reached clinical trials for the treatment of cancers with activating mutations in KRAS, BRAF, NRAS, MEK1/2, and ERK1/2 [22–27].